These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7510148)

  • 1. Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens.
    Gambacorti-Passerini C
    Int J Clin Lab Res; 1993; 23(4):186-91. PubMed ID: 7510148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New solid tumor targets for therapeutic monoclonal antibodies.
    Papkoff J
    Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and molecular analysis of p53 cellular-encoded tumor antigen.
    Rotter V; Wolf D
    Adv Cancer Res; 1985; 43():113-41. PubMed ID: 3887856
    [No Abstract]   [Full Text] [Related]  

  • 4. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
    Finn OJ
    Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
    Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
    J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
    Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
    Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Kirkin AF; Dzhandzhugazyan K; Zeuthen J
    Exp Clin Immunogenet; 1998; 15(1):19-32. PubMed ID: 9619397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-associated antigens recognized by cytotoxic T lymphocytes.
    Kirkin AF; Dzhandzhugazyan K; Zeuthen J
    APMIS; 1998 Jul; 106(7):665-79. PubMed ID: 9740504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide epitopes in breast cancer mucins.
    Xing PX; Apostolopoulos V; Trapani J; Prenzoska J; McKenzie IF
    Adv Exp Med Biol; 1994; 353():9-16. PubMed ID: 7527180
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel approach to production of antitumor monoclonal antibodies: antibody to a cell surface glycoprotein associated with transformation by a human oncogene.
    Roth JA; Scuderi P; Westin E; Gallo RC
    Surgery; 1984 Aug; 96(2):264-72. PubMed ID: 6379959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell-receptor-like antibodies - generation, function and applications.
    Dahan R; Reiter Y
    Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possibilities for active immunotherapy of human cancer.
    Hellström KE; Hellström I
    Cancer Invest; 1992; 10(4):285-93. PubMed ID: 1378351
    [No Abstract]   [Full Text] [Related]  

  • 14. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
    Ioannides CG; Whiteside TL
    Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
    Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
    Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cancer and virus antigens for cross-reactivity in human tissues.
    Jaravine V; Raffegerst S; Schendel DJ; Frishman D
    Bioinformatics; 2017 Jan; 33(1):104-111. PubMed ID: 27614350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.
    Markiewicz MA; Kast WM
    Cancer Invest; 2004; 22(3):417-34. PubMed ID: 15493363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.